title: Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group.
abstract: OBJECTIVE
  Pheochromocytoma (pheo) is the second component of the multiple endocrine neoplasia type 2 (MEN 2) syndrome. Clinical expression is sometimes poor, and chronology between medullary thyroid carcinoma (MTC) and pheo is not well evaluated. Therefore, a retrospective study was done in eight European countries in order to precise the main characteristics of pheo in MEN 2.
  
  
  METHODS
  Data from 300 MEN 2 patients with pheo (274 MEN 2 A and 26 MEN 2 B) were obtained from cases registered by the EuroMen study group, and collected by a medical standardized questionnaire. These cases occurred between 1969 and 1992.
  
  
  RESULTS
  Mean age at diagnosis of pheo was 39.5 years (range 14-68 years) in MEN 2A and 32.4 years (range 15-41 years) in MEN 2B patients. Pheo occurred first in 25.1% of the cases (2-15 years before diagnosis of MTC) and after MTC in 40.2% (2-11 years). In other cases (34.7%), MTC and pheo were diagnosed at the same time. Involvement was bilateral in 67.8% of cases. Malignancy was only 4%. Thirty-nine deaths occurred in these 300 patients, 64.1% were linked in pheo, 23.1% to MTC and 12.8% to other causes. Surgery was unilateral in 39.7% of the cases and bilateral adrenalectomy was the first procedure in 48.4%. A bilateral adrenalectomy in two steps had to be done in 11.9% of cases. In conclusion, these results justify systematic and prolonged biochemical screening of pheo during follow-up of MTC and address some questions about the best mode of surgery.
authors.affiliation: GETC, Hôpital Avicenne, Bobigny, France.
authors.forename: E
authors.initials: E
authors.lastname: Modigliani
authors.forename: H M
authors.initials: HM
authors.lastname: Vasen
authors.forename: K
authors.initials: K
authors.lastname: Raue
authors.forename: H
authors.initials: H
authors.lastname: Dralle
authors.forename: A
authors.initials: A
authors.lastname: Frilling
authors.forename: R G
authors.initials: RG
authors.lastname: Gheri
authors.forename: M L
authors.initials: ML
authors.lastname: Brandi
authors.forename: E
authors.initials: E
authors.lastname: Limbert
authors.forename: B
authors.initials: B
authors.lastname: Niederle
authors.forename: L
authors.initials: L
authors.lastname: Forgas
mesh_terms: D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D018276:Carcinoma, Medullary / Q000235:genetics; D003937:Diagnosis, Differential; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000150:complications*; D018814:Multiple Endocrine Neoplasia Type 2b / Q000150:complications*; D010673:Pheochromocytoma / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000235:genetics; D013997:Time Factors